U.S. Biotech Stock News

Earlier this month, Zscaler expanded its global data sovereignty capabilities on the Zero Trust Exchange, adding new regional control and logging planes, in-region SSL inspection and malware analysis, and options for local or on-premises log storage to help customers keep sensitive data within required jurisdictions. This push toward a more decentralized, jurisdiction-aware cloud architecture, backed by third-party validation and customer-controlled encryption keys, could make Zscaler’s...

Why Arrow Electronics is on investors’ radar now Arrow Electronics (ARW) has caught attention after recent trading left the stock around $140.89, with mixed shorter term moves that include an almost 10% decline over the past month and a stronger past 3 months. See our latest analysis for Arrow Electronics. Despite the recent 1 month share price return of negative 9.8% and a mild pullback in the last session, Arrow Electronics still shows stronger momentum when looking at its 3 month share...

In early March 2026, Amprius Technologies reported that full-year 2025 sales rose to US$73.01 million while net loss held near US$44.02 million, and it also filed a US$120.19 million shelf registration for 8,071,632 common shares linked to an ESOP-related offering. The company further issued 2026 guidance calling for revenue of at least US$125.00 million and a sharply reduced net loss of under US$8.00 million, highlighting a meaningful improvement in its expected earnings profile. Next,...

Westinghouse Air Brake Technologies recently reported a stronger-than-expected fourth-quarter 2025 performance and reaffirmed confident 2026 guidance, emphasizing double-digit adjusted EPS growth, record cash generation, and support from a multi-year backlog despite industry headwinds. Around the same time, Executive Vice President of Sales & Marketing Gina Trombley sold 4,013 shares, highlighting ongoing insider selling that contrasts with the company’s upbeat operational outlook. Next,...

AppLovin (APP) is drawing fresh attention after announcing a self-service advertising platform and a push into e-commerce advertising, targeting small and mid-sized developers while continuing share buybacks and leaning on its AI-powered tools. See our latest analysis for AppLovin. Despite the news around the self-service platform and e-commerce push, recent trading has been choppy, with a 17.55% 1 month share price return but a 25.75% year to date share price decline. The 1 year total...

JetBlue Airways stock: recent performance snapshot JetBlue Airways (JBLU) has drawn attention after a challenging period for the stock, with recent returns over the month and past 3 months under pressure, while the airline continues to operate across more than 100 destinations. See our latest analysis for JetBlue Airways. At a share price of $4.21, JetBlue’s 30 day share price return of a 28.76% decline and 1 year total shareholder return of a 24.01% loss point to fading momentum after a...

Chevron (CVX) is back in focus as the closure of the Strait of Hormuz and ongoing conflict in the Middle East tighten global crude supply, lift oil prices, and increase volatility across energy markets. See our latest analysis for Chevron. The share price performance has been strong, with a 6.3% 7 day share price return, a 7.7% 30 day share price return and a 32.4% 90 day share price return, while the 1 year total shareholder return of 28.7% indicates momentum that extends beyond the recent...

Upcoming earnings and analyst update put DLocal (DLO) in focus DLocal (DLO) heads into its Q4 2025 earnings release on March 18, 2026, with investors weighing recent results, fresh estimates, and an updated analyst view that keeps a positive rating but revises expectations. See our latest analysis for DLocal. The share price has been choppy ahead of the Q4 update, with a 3.17% one-day share price return contrasting with a 16.63% year-to-date share price decline. At the same time, the 1-year...

Cytokinetics recently announced that four presentations on MYQORZO™ (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy were delivered at the American College of Cardiology 2026 Annual Scientific Session, highlighting new analyses from the SEQUOIA-HCM, MAPLE-HCM, and FOREST-HCM trials. The data underscored that aficamten improved exercise capacity versus placebo and metoprolol, maintained efficacy across patients with and without hypertension, and showed reassuring safety...

Unity Software (U) is back in focus after a fresh round of analyst upgrades and positive commentary that emphasize its move toward new products, improving operating margin, and AI as a complementary tool. See our latest analysis for Unity Software. That interest is coming after a sharp reset in Unity's share price, with a 90 day share price return of a 54.11% decline and a year to date share price return of a 54.60% decline, even as the 1 year total shareholder return is a smaller 5.01%...

To put DTE Energy in context, you need to decide whether the current share price reflects fair value, a potential opportunity, or a risk of overpaying. DTE Energy's share price closed at US$149.34, with total returns of 1.1% over 7 days, 3.0% over 30 days, 14.6% year to date, 14.0% over 1 year, 55.8% over 3 years and 60.5% over 5 years. This gives you a useful snapshot of how the stock has behaved over different time frames. Recent company specific news has focused on DTE Energy's role as a...

Brady (BRC) is back on many investors’ screens after a recent shift in its share performance, with the stock flat over the past day but showing mixed moves over the past month and over the past 3 months. See our latest analysis for Brady. With the share price at $85.99, Brady’s recent 30 day share price return of 10.73% decline contrasts with a 9.33% share price gain year to date and a 21.91% total shareholder return over the past year. This suggests momentum has cooled after a stronger...

Experis, a ManpowerGroup brand, recently launched its EXCELERATE AI enterprise AI agent services portfolio and Enterprise AI Services Suite, partnering with SoundHound AI to deploy and manage conversational AI agents at scale for large organizations, initially focusing on sectors such as US healthcare. This move extends ManpowerGroup’s role beyond technology staffing into building and orchestrating AI-powered automation for clients, potentially deepening relationships and expanding...

Zions Bancorporation, N.A. recently became the focus of a securities fraud investigation after disclosing apparent misrepresentations and contractual defaults on two commercial and industrial loans in its California Bank & Trust division, prompting full provisioning and significant charge‑offs. At the same time, Zions is hosting a fraud prevention conference and has taken a lead role arranging a US$490 million credit facility for Varex Imaging, underscoring its dual position as both a risk...

On March 10, 2026, Markel Insurance appointed Kristen Dardia as Head of Portfolio Analytics for the US and Bermuda, tasking her with leading advanced analytics, technical pricing, and portfolio management after nearly two decades in actuarial science, analytics, and business strategy. Her track record embedding analytics into underwriting and portfolio decisions could meaningfully influence how Markel Group refines risk selection and pricing across its specialty insurance operations. Next,...

If you are wondering whether Sterling Infrastructure's recent run leaves any value still on the table, a good starting point is understanding what the current share price is really implying. Sterling Infrastructure recently closed at US$425.51, with returns of 3.4% over the last 7 days, a 2.8% decline over 30 days, 33.3% year to date and 260.5% over 1 year, alongside very large 3 year and 5 year gains. Recent attention on Sterling Infrastructure has largely centered on its sharp share price...

Snowflake recently presented at the HIMSS 2026 Global Health Conference and the 3rd Billington State and Local CyberSecurity Summit, underscoring its push into healthcare and public-sector data and security use cases. These appearances come as Snowflake highlights over 430 new AI features and deep partnerships with Anthropic, Google Cloud, and OpenAI, reflecting a broadening role in enterprise AI workloads. Now we’ll examine how Snowflake’s rapid rollout of hundreds of new AI capabilities...

Blue Bird (BLBD) has drawn fresh investor attention after analysts raised their consensus earnings estimate, even though they expect quarterly earnings per share of $0.81 to be below the level reported in the prior year. See our latest analysis for Blue Bird. The latest 1 day share price return of 1.19% and 7 day return of 2.00% sit against a softer 30 day share price return of 5.38%. Total shareholder returns of 56.00% over one year and 165.42% over three years point to momentum that has...

CSX expanded its Select Site initiative by awarding its designation to 21 new rail served properties across 10 states. Owens Corning announced a large manufacturing investment at a CSX Silver Select Site in Alabama, tied to about 100 new skilled jobs. This development reflects fresh industrial interest in CSX served locations, beyond recent discussions focused on valuation, margin outlook, and service metrics for NasdaqGS:CSX. For investors tracking NasdaqGS:CSX, this move adds a fresh...

NIKE (NKE) is back in focus after Barclays shifted to a more positive stance on the stock, citing operational progress, cleaner financial metrics, and tighter management discipline ahead of key upcoming earnings. See our latest analysis for NIKE. Despite Barclays turning more positive, the recent 30 day share price return of a 12.69% decline and the 90 day share price return of a 16.09% decline show momentum has been weak, and the 1 year total shareholder return of a 22.93% loss points to an...

Planet Labs PBC (PL) has drawn investor attention after a recent double digit one-day move, adding to gains over the past month and past 3 months, prompting a closer look at its current setup. See our latest analysis for Planet Labs PBC. That 10.1% 1 day share price return and 20.8% 30 day share price return feed into a much bigger move, with momentum reinforced by a 64.4% 90 day share price return and a very large 1 year total shareholder return. If you are interested in what else is moving...

Insulet (PODD) is in focus after disclosing an internal tubing defect in certain Omnipod 5 Pod lots, prompting a voluntary Medical Device Correction and free replacements. Production and new patient starts are expected to continue. See our latest analysis for Insulet. The tubing defect news has landed against a weak recent share price backdrop, with the 90 day share price return at a 20.4% decline and the 1 year total shareholder return at an 11.5% loss. This suggests that momentum has been...

In March 2026, Aldeyra Therapeutics reported that the FDA issued a Complete Response Letter for its reproxalap dry eye disease NDA, citing insufficient and inconsistent evidence of efficacy despite no safety or manufacturing concerns. An important nuance is that the FDA did not request new trials, instead urging Aldeyra to clarify why certain studies failed and where reproxalap might work best. We’ll now examine how the FDA’s efficacy concerns and lack of requested new trials reshape...

In early 2026, a joint SONAR and Ryder System report showed tender rejection rates climbing to nearly 14.3% in early February, reaching levels last seen during the pandemic and pointing to tightening trucking capacity. This spike in rejection rates hints at a shifting freight balance that could influence pricing power and operational conditions for logistics providers like Ryder. We’ll now examine how this jump in tender rejection rates could influence Ryder’s existing investment narrative...